Advertisement
Document › Details
Xlife Sciences AG. (11/4/19). "Press Release: Xlife Siences AG. New Project in the Portfolio". Zurich.
Organisation | Xlife Sciences AG (SIX: XLS) | |
Organisation 2 | Saniva Diagnostics GmbH | |
Product | diagnostic device, clinical | |
Product 2 | venture capital | |
Index term | Saniva Diagnostics–Xlife Sciences: investment, 201911 investment by Xlife Sciences AG in Saniva Diagnostics GmbH | |
We are pleased to announce that Xlife Sciences AG has added saniva diagnostics GmbH to the portfolio.
saniva diagnostics GmbH
Detecting diseases at an early stage is crucial to modern medical science. The timing of a diagnosis can significantly impact the chances of healing and the effectiveness of therapy. saniva diagnostics GmbH, a spin-off of the University Hospital Jena is developing a screening instrument to detect neurodegenerative diseases such as Parkinson or dementia at a very early stage. This screening instrument works by analyzing human movement. For more information, please visit: www.sanivadiagnostics.com
Xlife Sciences AG
Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and futureoriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch
Record changed: 2023-06-05 |
Advertisement
More documents for Xlife Sciences AG (SIX: XLS)
- [1] 4D Lifetec AG. (10/18/23). "Press Release: 4D Lifetec Secures CHF 23.3 Mio in a Share and Investment Deal with Xlife Sciences Opening New Horizons in Using AI and Digital Health in Early Cancer Detection". Zürich & Cham....
- [2] Xlife Sciences AG. (11/21/22). "Press Release: Xlife Sciences Initiates a Review of Strategic Options". Zürich....
- [3] Xlife Sciences AG. (1/10/22). "Press Release: Xlife Sciences Plans Listing on the »Sparks« Segment of SIX Swiss Exchange". Zürich....
- [4] Xlife Sciences AG. (12/1/21). "Press Release: Xlife Sciences AG (XLS DE) Appoints New Chief Financial Officer". Zürich....
- [5] Indivumed GmbH. (3/18/21). "Press Release: Indivumed Announces Expansion into Drug Development, Formation of Ix Therapeutics. Joint Venture with Xlife Sciences". Hamburg....
- [6] Velabs Therapeutics GmbH. (1/7/20). "Press Release: Velabs Therapeutics Receives Exclusive Licence from Alytas Therapeutics for the Development of Therapeutic Antibodies as Senolytics". Heidelberg & Jena....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top